
    
      Trametinib (SNR1611) is a MEK inhibitor that downregulates the MAPK/ERK pathway. In this
      study, the potential of MAPK/ERK pathway downregulation through trametinib (SNR1611) as a
      therapeutic treatment for amyotrophic lateral sclerosis (ALS) will be evaluated.
    
  